prof. dr. Marc Peeters
- ORCID iD
- 0000-0003-4969-2303
Show
Sort by
-
High levels of cell-free DNA (cfDNA) at baseline (BL) and increase of at least one mutation at day 14 (D14) as independent prognostic biomarkers for patients (pts) with advanced colorectal cancer (aCRC) under regorafenib
-
Circulating tumor DNA detects early response to regorafenib in advanced colorectal cancer
-
Baseline cell-free DNA (cfDNA) and metabolic tumor volume (MTV) independently predict outcome in metastatic chemorefractory colorectal cancer (mCRC)
-
- Journal Article
- A2
- open access
Children's International Polyposis (CHIP) study : a randomized, double-blind, placebo-controlled study of celecoxib in children with familial adenomatous polyposis
-
- Journal Article
- A1
- open access
Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer : the SIRFLOX study
-
Regorafenib assessment guided by metabolic imaging in refractory advanced colorectal cancer (aCRC) : REGARD-C study
-
Standardized added metabolic activity (SAM) IN 18F-FDG PET assessment of treatment response in colorectal liver metastases
-
The treatment of peritoneal carcinomatosis of colorectal cancer with complete cytoreductive surgery and hyperthermic intraperitoneal peroperative chemotherapy (HIPEC) with oxaliplatin: a Belgian multicentre prospective phase II clinical study
-
Single-photon emission computed tomographic imaging of the early time course of therapy-induced cell death using technetium 99m tricarbonyl His-annexin A5 in a colorectal cancer xenograft model
-
A phase II randomized study of combined infusional leucovorin sodium and 5-FU versus the leucovorin calcium followed by 5-FU both in combination with irinotecan or oxaliplatin in patients with metastatic colorectal cancer
-
Comparison of magnetic resonance imaging and histopathological response to chemoradiotherapy in locally advanced rectal cancer
-
Intrapatient cetuximab dose escalation in metastatic colorectal cancer according to the grade of early skin reactions: the randomized EVEREST study
-
Value of DCE-MRI and FDG-PET/CT in the prediction of response to preoperative chemotherapy with bevacizumab for colorectal liver metastases
-
Short course chemotherapy followed by concomitant chemoradiotherapy and surgery in locally advanced rectal cancer: a randomized multicentric phase II study
-
An evaluation of FDG-PET as a predictor of metabolic response to chemotherapy in metastatic colorectal cancer patients (mCRC)
-
- Miscellaneous
- open access
Assurance de qualité pour le cancer rectal : phase 3 : méthodes statistique visant à comparer les centres sur base d'un ensemble d'indicateurs de qualité
-
Assessment of tumor genotypes in metastatic colorectal cancer (MCRC): mutations beyond KRAS codons 12 and 13 as predictive biomarkers of response to panitumumab (PMAB) in a randomized, phase 3 study
-
Evaluation of panitumumab (PMAB) plus folfiri versus folfiri alone as second-line therapy in patients (PTS) with metastatic colorectal cancer (MCRC) receiving prior bevacizumab (BEV) in study 20050181
-
Panitumumab (PMAB) in combination with chemotherapy (CT) versus CT alone: health-related quality of life (HRQOL) in patients (PTS) with wild-type (WT) KRAS metastatic colorectal cancer (MCRC)
-
In vivo imaging of apoptosis in oncology : an update
-
99mTc-(CO)3 His-annexin A5 micro-SPECT demonstrates increased cell death by irinotecan during the vascular normalization window caused by bevacizumab
-
- Conference Paper
- C3
- open access
Efficacy of the combined use of bevacizumab and irinotecan in a human colorectal cancer xenograft model analysed by SPECT imaging
-
- Conference Paper
- C3
- open access
FDG-PET is a predictor of metabolic response to chemotherapy in metastatic colorectal cancer (mCRC)
-
- Conference Paper
- C3
- open access
Preoperative chemotherapy for colorectal liver metastases : prediction of response by DCE-MRI abd FDG-PET/CT?
-
- Conference Paper
- C3
- open access
PET as a predictor of metabolic response to antiangiogenic therapy in metastatic colorectal cancer (mCRC)
-
- Conference Paper
- C3
- open access
Cystic masses of the pancreas : how useful is cyst fluid analysis in the diagnosis?
-
- Journal Article
- A2
- open access
'Doe-het-zelf chemotherapie advies' : gevaarlijke ontwikkelingen via het worldwide web
-
Familial adenomatous polyposis: clinical presentation, detection and surveillance
-
MDM2 gene amplification and protein expressions in colon carcinoma: is targeting MDM2 a new therapeutic option?
-
FDG uptake in primary squamous cell carcinoma of the head and neck : the relationship between overexpression of glucose transporters and hexokinases, tumour proliferation and apoptosis
-
Assessment of neovascular permeability in a pancreatic tumor model using dynamic contrast-enhanced (DCE) MRI with contrast agents of different molecular weights
-
EGFR in melanoma : clinical significance and potential therapeutic target
-
Noninvasive monitoring of therapy-induced microvascular changes in a pancreatic cancer model using dynamic contrast-enhanced magnetic resonance imaging with P846, a new low-diffusible gadolinium-based contrast agent
-
EUS predicts local resection for rectal cancer
-
Psychometric evaluation of the FACT colorectal cancer symptom index (FCSI-9): reliability, validity, responsiveness, and clinical meaningfulness
-
Diarrhea and the rationale to use Sandostatin®
-
A phase Ib/IIa trial to evaluate the CCK2 receptor antagonist Z-360 in combination with gemcitabine in patients with advanced pancreatic cancer
-
EORTC Elderly Task Force experts' opinion for the treatment of colon cancer in older patients
-
Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy
-
Role of cell cycle perturbations in the combination therapy of chemotherapeutic agents and radiation
-
In vivo toxicity and bioavailability of taxol (R) and a paclitaxel/beta-cyclodextrin formulation in a rat model during HIPEC
-
Adjuvant gemcitabine alone versus gemcitabine-based chemoradiotherapy after curative resection for pancreatic cancer: a randomized EORTC-40013-22012/FFCD-9203/GERCOR phase II study
-
Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer
-
Deoxycitidine kinase is associated with prolonged survival after adjuvant gemcitabine for resected pancreatic adenocarcinoma
-
KRAS mutation detection and prognostic potential in sporadic colorectal cancer using high-resolution melting analysis
-
In vitro and in vivo evaluation of [99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection of phosphatidylserine-expressing cells
-
EUS predicts local resection for rectal cancer
-
SPECT imaging of apoptotic tumor response in a colorectal tumor model
-
- Journal Article
- A1
- open access
Epidermal growth factor receptor and K-RAS status in two cohorts of squamous cell carcinomas
-
The low-molecular-weight heparin, nadroparin, inhibits tumour angiogenesis in a rodent dorsal skinfold chamber model